Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company achieved a significant increase in revenue and net profit in 2024, with operating income reaching 101.31 billion yuan, up 22.6% year-on-year, and net profit attributable to shareholders at 1.20 billion yuan, up 50.8% year-on-year [6] - The company is the largest polyester filament manufacturer in China and is expected to benefit from industry recovery and new capacity investments in regions like Fujian and Anhui [9] - The report anticipates a steady increase in net profit for 2025-2027, projecting net profits of 2.02 billion yuan, 2.99 billion yuan, and 3.41 billion yuan, respectively, with corresponding EPS of 0.84 yuan, 1.24 yuan, and 1.42 yuan [9] Financial Performance Summary - In Q4 2024, the company reported a revenue of 25.26 billion yuan, a year-on-year increase of 20.9%, and a net profit of 195 million yuan, up 283.2% year-on-year [6] - For Q1 2025, the company recorded a revenue of 19.42 billion yuan, down 8.0% year-on-year, but net profit increased by 5.4% year-on-year to 611 million yuan [6] - The company’s polyester production capacity is approximately 13 million tons per year, and it plans to add two new production lines in 2025, which are expected to enhance profit margins [6][9] Industry Outlook - The growth rate of polyester filament production capacity is expected to slow down, with a projected CAGR of 1.5% from 2024 to 2026, down from 7.1% from 2017 to 2023 [7] - The demand for polyester filament is projected to increase by 18% in 2024, with an absolute increment of nearly 5 million tons, indicating a positive market outlook [7] - The industry is undergoing consolidation, with the market share of the top six companies increasing from 48% in 2018 to 66% in 2023, suggesting a more favorable competitive environment for larger manufacturers [7]

[Table_Main] 证券研究报告 | 固定收益点评 2025 年 5 月 12 日 固定收益点评 证券分析师 吕品 资格编号：S0120524050005 邮箱：lvpin＠tebon.com.cn 严伶怡 资格编号：S0120524110003 邮箱：yanly＠tebon.com.cn 研究助理 货币资金面 请务必阅读正文之后的信息披露和法律声明 本周（5.6-5.9，下同）共有 16178 亿元逆回购到期。周二至周五央行分别投放逆 回购 4050、1955、1586、770 亿元，期间累计投放 8361 亿元逆回购，全周净回 笼流动性 7817 亿元。本周资金价格下行，截至 5 月 9 日，R001、R007、DR001、 DR007 分别为 1.52%、1.58%、1.49%、1.54%，较 4 月 30 日分别变动-33.21BP、 -25.91BP、-29.45BP、-25.77BP，分别位于 22%、9%、20%、3%历史分位数。 本周资金主要融出方净融入规模减少。本周资金主要融出方净融入规模减少。主要 融出机构（大行/政策行与股份行）全周（5.6-5.9）净融入-4639 亿元，与前一周 ...

所属行业：计算机/IT 服务Ⅱ 当前价格(元)：50.85 证券分析师 买入（首次） 陈涵泊 资格编号：S0120524040004 邮箱：chenhb3＠tebon.com.cn 研究助理 王思 邮箱：wangsi＠tebon.com.cn 市场表现 -34% 0% 34% 69% 103% 137% 171% 206% 2024-05 2024-09 2025-01 博睿数据 沪深300 | 沪深300对比 | 1M | 2M | 3M | | --- | --- | --- | --- | | 绝对涨幅(%) | 12.75 | -12.64 | -3.88 | | 相对涨幅(%) | 10.20 | -10.23 | -2.92 | | 资料来源：德邦研究所，聚源数据 | | | | 相关研究 [Table_Main] 证券研究报告 | 公司首次覆盖 博睿数据(688229.SH) 2025 年 05 月 12 日 博睿数据：拥抱华为与字节，新 产品或进放量周期 投资要点 | [Table_Base] 股票数据 | | [Table_Finance] 主要财务数据及预测 | | | | | | | - ...

买入（首次） 市场表现 -34% 0% 34% 69% 103% 137% 171% 206% 2024-05 2024-09 2025-01 博睿数据 沪深300 | 沪深300对比 | 1M | 2M | 3M | | --- | --- | --- | --- | | 绝对涨幅(%) | 12.75 | -12.64 | -3.88 | | 相对涨幅(%) | 10.20 | -10.23 | -2.92 | | 资料来源：德邦研究所，聚源数据 | | | | 相关研究 所属行业：计算机/IT 服务Ⅱ 当前价格(元)：50.85 证券分析师 陈涵泊 资格编号：S0120524040004 邮箱：chenhb3＠tebon.com.cn 研究助理 王思 邮箱：wangsi＠tebon.com.cn | [Table_Base] 股票数据 | | [Table_Finance] 主要财务数据及预测 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 总股本(百万股)： | 44.40 | | 2023A | 2024A | 2025 ...

[Table_Main] 海外市场周报 证券分析师 薛威 资格编号：S0120523080002 邮箱：xuewei＠tebon.com.cn 谭诗吟 资格编号：S0120523070007 邮箱：tansy＠tebon.com.cn 证券研究报告 | 海外市场周报 2025 年 05 月 11 日 静待破局 [Table_Summary] 投资要点： 请务必阅读正文之后的信息披露和法律声明 上周全球股市涨跌参半。越南 VN30 指数领涨全球主要市场。美股三大指数集体回 调，道指、纳指和标普 500 涨跌幅分别为-0.2%、-0.3%和-0.5%；欧洲市场三大主 要指数表现分化，德国 DAX 指数上涨 1.8%，法国 CAC40 和英国富时 100 指数 小幅回调；亚太地区涨多跌少，仅恒生科技和印度 SENSEX30 指数回调。 美英协议的标杆作用大于实际意义。北京时间 5 月 8 日晚间，特朗普公布了美英 经贸谈判达成的协议一般条款，英国也成为了 4 月初全球"关税战"后首个与美国 达成经贸协议的国家。从大体内容上看，有三点值得重视：第一，基础关税 10% 得到保留，这也是 4 月初美国公布的对各国加征关税 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2]. Core Insights - The report highlights a significant rebound in the stock prices of leading US healthcare AI companies, with Tempus and Grail both experiencing a 65% increase over the past month. This sector is noted for its rapid implementation and growing investor interest [8][10]. - It suggests focusing on domestic companies that are likely to benefit from the overseas AI healthcare performance, specifically mentioning companies like RunDa Medical and YiMaiTong as having strong potential for AI-driven revenue growth [5][10]. Summary by Sections 1. Focus on US AI Leaders and Domestic Opportunities - The report emphasizes the recent stock price rebounds of US healthcare AI leaders, with notable increases of 65% for Tempus and Grail, and suggests that AI in healthcare is one of the fastest-growing fields [8]. - It recommends monitoring companies such as RunDa Medical, YiMaiTong, and others that are expected to achieve rapid AI performance growth [10]. 2. Weekly Market Review and Hotspot Tracking (May 6 - May 9, 2025) - The report notes that the Shenwan Pharmaceutical and Biotechnology Index rose by 1.01% during the week, underperforming the CSI 300 Index by 1.0%. Year-to-date, the index has increased by 1.19%, outperforming the CSI 300 by 3.44% [32]. - The top five performing stocks during this period included Changshan Pharmaceutical (up 23.59%), Xiangxue Pharmaceutical (up 19.64%), and others [44]. 3. Company Highlights - RunDa Medical has established deep collaborations with Huawei for AI applications across various healthcare settings, providing digital solutions to over 80 hospitals by the end of 2024 [12][13]. - YiMaiTong, a leading online professional physician platform, has seen its registered physician count grow from 228,000 in 2018 to 867,000 in 2024, with a compound annual growth rate (CAGR) of 24.9% [17][20]. The company’s revenue increased from 83.46 million yuan to 558.46 million yuan from 2018 to 2024, reflecting a CAGR of 37.3% [20]. 4. Monthly Investment Portfolio - The report lists a monthly investment portfolio that includes companies such as Kangfang Biotech, Zai Lab, and others, indicating a focus on innovative drugs and companies with emerging performance [5]. 5. Market Valuation and Trading Volume - As of May 9, 2025, the overall valuation of the Shenwan Pharmaceutical sector was 32.3, with a slight increase from the previous week [38]. The total trading volume for the sector reached 287.2 billion yuan, accounting for 5.3% of the total A-share trading volume [40].

[Table_Main] 证券研究报告 | 行业周报 医药生物 优于大市（维持） 证券分析师 周新明 资格编号：S0120524060001 邮箱：zhouxm＠tebon.com.cn 研究助理 市场表现 -29% -22% -15% -7% 0% 7% 15% 22% 2024-05 2024-09 2025-01 医药生物 沪深300 资料来源：德邦研究所，聚源数据 相关研究 1.《博瑞医药：专注代谢药物研发， 管线新增口服 BGM0504 与 Amylin 类似物》，2025.4.28 2.《医药行业周报：生命科学产业链： 需求端逐步回暖，关税战进一步催化 国产替代》，2025.4.21 3.《再鼎医药(09688.HK)：艾加莫德 新剂型获 FDA 批准，不惧竞争，大 单品销售可期》，2025.4.14 4.《医药行业周报：中美互加关税背 景 下 ， 如 何 布 局 医 疗 消 费 》， 2025.4.13 5.《医药行业周报：中国创新药逐步 进入收获期，关注技术革新与 BD 潜 力》，2025.4.6 医药行业周报：美股医疗 AI 龙头股价 反弹，关注 AI 快速落地的企业 [Table_Summ ...

Investment Rating - The report maintains an "Outperform" rating for the basic chemical industry [2] Core Viewpoints - The basic chemical sector has outperformed the market, with the industry index rising by 2.1% from April 30 to May 9, 2025, compared to a 1.9% increase in the Shanghai Composite Index [6][17] - The report highlights the widening price gap between domestic and international nitrogen and phosphorus fertilizers, indicating potential export opportunities [6][27] - The domestic urea production is projected to reach 67.54 million tons in 2024, with a supply surplus expected due to limited export policies [28] - The report suggests that the chemical industry may enter a new long-term prosperity cycle, driven by recent policy changes and supply-side reforms [14][15] Summary by Sections 1. Core Viewpoints - The report emphasizes that the chemical industry is likely to benefit from recent government policies aimed at boosting demand and stabilizing the economy [14] - It identifies four main investment themes: core assets entering a long-term value zone, industries with supply constraints showing elasticity, demand certainty in specific sectors, and high-dividend resource stocks [15] 2. Overall Performance of the Chemical Sector - The basic chemical industry index has shown a year-to-date increase of 3.3%, outperforming both the Shanghai Composite and ChiNext indices [17][21] 3. Individual Stock Performance in the Chemical Sector - Among 424 stocks in the basic chemical sector, 364 stocks rose, with notable gainers including Heng Tian Hai Long (+23.6%) and Yu San Xia A (+23.2%) [25][26] 4. Key News and Company Announcements - A meeting was held by the National Development and Reform Commission to discuss the export of fertilizers, emphasizing a principle of prioritizing domestic supply while allowing for controlled exports [27] - The report notes significant price differences for urea and phosphate fertilizers between domestic and international markets, suggesting potential for increased exports if policies change [28]

煤炭 优于大市（维持） 证券分析师 翟堃 资格编号：s0120523050002 邮箱：zhaikun＠tebon.com.cn 研究助理 谢佶圆 邮箱：xiejy＠tebon.com.cn 市场表现 -34% -26% -17% -9% 0% 9% 17% 26% 2024-05 2024-09 2025-01 煤炭开采 沪深300 资料来源：聚源数据、德邦研究所 相关研究 1.《永泰能源（600157.SH）：煤炭 主业以量补价，煤电协同稳步推 进》，2025.4.29 2.《煤炭周报：宏观预期强化，重 视板块底部布局》，2025.4.27 3.《煤炭周报：煤价震荡寻底，关 注板块红利属性》，2025.4.20 4.《煤炭行业月报：3 月进口同比转 负 ， 静 待 后 续 需 求 改 善 》， 2025.4.18 5.《煤炭周报：煤价底部企稳，回 购增持彰显板块价值》，2025.4.12 煤炭周报: 板块业绩有望筑底， 寻找相对确定性机会 [Table_Summary] 投资要点： 煤炭开采 2025 年 05 月 11 日 请务必阅读正文之后的信息披露和法律声明 证券研究报告 | 行业周报 25Q1 业 ...

煤炭 优于大市（维持） 证券分析师 翟堃 资格编号：s0120523050002 邮箱：zhaikun＠tebon.com.cn 研究助理 谢佶圆 邮箱：xiejy＠tebon.com.cn 市场表现 -34% -26% -17% -9% 0% 9% 17% 26% 2024-05 2024-09 2025-01 煤炭开采 沪深300 资料来源：聚源数据、德邦研究所 相关研究 1.《永泰能源（600157.SH）：煤炭 主业以量补价，煤电协同稳步推 进》，2025.4.29 2.《煤炭周报：宏观预期强化，重 视板块底部布局》，2025.4.27 3.《煤炭周报：煤价震荡寻底，关 注板块红利属性》，2025.4.20 4.《煤炭行业月报：3 月进口同比转 负 ， 静 待 后 续 需 求 改 善 》， 2025.4.18 5.《煤炭周报：煤价底部企稳，回 购增持彰显板块价值》，2025.4.12 煤炭开采 2025 年 05 月 11 日 请务必阅读正文之后的信息披露和法律声明 证券研究报告 | 行业周报 25Q1 业绩同环比下滑，寻找相对确定性投资机会。据 CCTD 中国煤炭市场网， 2024 年煤炭全行业实现 ...